AZN

AstraZeneca plc -13.2% potential downside indicated by Deutsche

AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -13.2% according to Deutsche.Deutsche set a target price of 10,500 GBX for the company, which when compared to the..

May 3, 2024

AstraZeneca plc -13.0% potential downside indicated by Deutsche

AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -13.0% according to Deutsche.Deutsche set a target price of 10,500 GBX for the company, which when compared to the..

April 26, 2024

AstraZeneca plc -13.0% potential downside indicated by Deutsche

AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -13.0% according to Deutsche.Deutsche set a target price of 10,500 GBX for the company, which when compared to the..

April 26, 2024

AstraZeneca plc 13.8% potential upside indicated by Barclays

AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 13.8% according to Barclays.Barclays set a target price of 12,500 GBX for the company, which when compared to the..

April 12, 2024

AstraZeneca Plc to increase Dividend by 7% for 2024

AstraZeneca plc (LON:AZN) announces a 7% increase in annual dividend for 2024 to $3.10 per share, reflecting confidence in performance and cash generation...

April 11, 2024

AstraZeneca Plc’s Enhertu approved in the US for HER2+ solid tumours

AstraZeneca plc and Daiichi Sankyo's Enhertu has gained US approval for treating HER2-positive solid tumours, marking a significant advancement in cancer treatment...

April 8, 2024

AstraZeneca’s Imfinzi shows positive results in Phase III trial for small cell lung cancer

AstraZeneca's Imfinzi shows significant improvement in overall survival and progression-free survival in limited-stage small cell lung cancer patients after chemoradiotherapy. Exciting breakthrough in treatment...

April 5, 2024

AstraZeneca’s Voydeya approved in the US as add-on therapy for PNH patients with EVH

AstraZeneca's Voydeya (danicopan) has been approved in the US as add-on therapy for PNH patients with EVH. Find out more about this breakthrough treatment...

April 2, 2024

AstraZeneca Ultomiris granted approval in US for treatment of adults with neuromyelitis optica spectrum disorder

Ultomiris, the first long-acting C5 complement inhibitor, shows promise in reducing relapse risk for AQP4 Ab+ NMOSD patients. Learn more here...

March 25, 2024

AstraZeneca expands late-stage rare disease pipeline with Amolyt Pharma acquisition

AstraZeneca plc (LON:AZN) has entered an agreement to acquire Amolyt Pharma, focusing on treatments for rare endocrine diseases, including hypoparathyroidism...

March 14, 2024

AstraZeneca plc -6.2% potential downside indicated by Deutsche

AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -6.2% according to Deutsche.Deutsche set a target price of 9,500 GBX for the company, which when compared to the..

March 7, 2024

AstraZeneca and Daiichi Sankyo’s Dato-DXd validated by EMA for lung and breast cancer treatment

AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd) receives EMA validation for lung and breast cancer treatments, advancing the potential for improved patient outcomes...

March 4, 2024

AstraZeneca plc -5.4% potential downside indicated by Deutsche

AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -5.4% according to Deutsche.Deutsche set a target price of 9,500 GBX for the company, which when compared to the..

March 1, 2024

AstraZeneca’s Voydeya recommended for PNH treatment in EU

AstraZeneca's Voydeya for PNH patients is recommended for EU approval. Learn about this promising treatment and its potential benefits for patients...

February 26, 2024

AstraZeneca plc 24.6% potential upside indicated by JP Morgan Cazenove

AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 24.6% according to JP Morgan Cazenove.JP Morgan Cazenove set a target price of 12,500 GBX for the company, which..

February 22, 2024

AstraZeneca’s Tagrisso plus chemotherapy appoved for lung cancer in the US

AstraZeneca's Tagrisso approved in the US for EGFRm non-small cell lung cancer with chemotherapy. FLAURA2 trial results show significant benefit...

February 19, 2024

AstraZeneca reports Strong Growth and Pipeline Momentum in FY and Q4 2023

AstraZeneca reports strong FY and Q4 2023 results, with revenue growth, new medicine approvals, and optimistic growth projections for 2024...

February 8, 2024

AstraZeneca plc 21.2% potential upside indicated by Jefferies

AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 21.2% according to Jefferies.Jefferies set a target price of 12,500 GBX for the company, which when compared to the..

December 29, 2023

AstraZeneca’s Wainua receives FDA approval in the US

AstraZeneca plc (LON:AZN) and Ionis’ Wainua (eplontersen) has been approved in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN..

December 22, 2023

AstraZeneca plc 23.5% potential upside indicated by Jefferies

AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 23.5% according to Jefferies.Jefferies set a target price of 12,500 GBX for the company, which when compared to the..

December 12, 2023

News and Interview Alerts

Company Presentations

Valeura Energy Q2 2023 Results by Sean Guest CEO

Accrol Group Holdings Investor Presentation 2023

TEAM Plc’s Mark Clubb reviews 2022 and sets out the Company plans for 2023

Enteq Technologies Investor Presentation 2023

Q&As

Ilika’s Graeme Purdy on first commercial Stereax electrode delivery (LON:IKA)

14 March 2026

Hardman & Co

Cavendish plc: Solid performance in still tough markets

30 June 2026

Cavendish plc delivers solid performance in tough markets

24 June 2026

ICG Enterprise Trust FY’26 results: look to future realisations

11 June 2026

NB Private Equity Partners 2025 results: Looking to future realisations

29 May 2026

Chesnara Plc: Showing good operational progress

17 April 2026

Green News

Ilika raises £4.56m in oversubscribed placing and subscription

3 July 2026

Ilika launches Retail Offer to raise up to £0.5 Million

3 July 2026

Net Zero Infrastructure appoints Clear Capital Markets as broker

1 July 2026

Firering Strategic Minerals reports annual results, advances Limeco growth

30 June 2026

View all Sustainable sectors, Plcs and news >>

Search

Latest Interviews

Real Estate Credit Investments: 10% Yield Strategy Backed by Senior Secured Property Lending (Video)

BrokerTalk

Likewise Group FY25 Results Highlight Ongoing Growth Momentum, Zeus

29 April 2026

Verici Dx Shows Strong Momentum with Impressive Q1 Growth, Singer Capital Markets

28 April 2026

Record’s Inflows Reinforce Confidence in Growth Pipeline

27 April 2026

Cora Gold Funding Deal Takes Sanankoro to Fully Funded Status, Says Hannam & Partners

24 April 2026

Funds

TEAM plc completes acquisition of EPIC Book

1 July 2026

Geiger Counter reports 21.6% NAV increase in interim results

30 June 2026

Fidelity China Special Situations outperforms amid China’s tech revival (LON: FCSS)

30 June 2026

Fidelity Asian Values sees investors rotate into Asian small-cap value

30 June 2026

Fidelity European Trust outperforms on technology and utilities strength (LON: FEV)

30 June 2026

View all Funds, Market Insights and news >>

FTSE 100 News

Barratt Redrow appoints new Chief Financial Officer

19 June 2026

Tesco Q1 sales rise as customer satisfaction improves, reiterates full-year guidance

18 June 2026

Whitbread Q1 sales rise as UK hotels outperform and Germany grows strongly

18 June 2026

Informa reports 6.4% underlying revenue growth in five-month trading update

18 June 2026

UK Broker Ratings

FIRSTGROUP PLC ORD 5P (FGP.L)

30 June 2026

Goodwin PLC (GDWN.L) Stock Analysis: Unpacking 27.5% Revenue Growth in the Industrials Sector

30 June 2026

CHEMRING GROUP PLC ORD 1P (CHG.L)

30 June 2026

Hilton Food Group PLC (HFG.L) Stock Analysis: Navigating High Dividend Yields and Growth Prospects

30 June 2026

Auction Technology Group PLC (ATG.L): Investor Outlook Reveals 28% Potential Upside in the Evolving Online Auction Space

30 June 2026

AZN

AstraZeneca plc -13.2% potential downside indicated by Deutsche

May 3, 2024

AstraZeneca plc -13.0% potential downside indicated by Deutsche

April 26, 2024

AstraZeneca plc -13.0% potential downside indicated by Deutsche

April 26, 2024

AstraZeneca plc 13.8% potential upside indicated by Barclays

April 12, 2024

AstraZeneca Plc to increase Dividend by 7% for 2024

AstraZeneca plc (LON:AZN) announces a 7% increase in annual dividend for 2024 to $3.10 per share, reflecting confidence in performance and cash generation...

April 11, 2024

AstraZeneca Plc’s Enhertu approved in the US for HER2+ solid tumours

AstraZeneca plc and Daiichi Sankyo's Enhertu has gained US approval for treating HER2-positive solid tumours, marking a significant advancement in cancer treatment...

April 8, 2024

AstraZeneca’s Imfinzi shows positive results in Phase III trial for small cell lung cancer

April 5, 2024

AstraZeneca’s Voydeya approved in the US as add-on therapy for PNH patients with EVH

AstraZeneca's Voydeya (danicopan) has been approved in the US as add-on therapy for PNH patients with EVH. Find out more about this breakthrough treatment...

April 2, 2024

AstraZeneca Ultomiris granted approval in US for treatment of adults with neuromyelitis optica spectrum disorder

Ultomiris, the first long-acting C5 complement inhibitor, shows promise in reducing relapse risk for AQP4 Ab+ NMOSD patients. Learn more here...

March 25, 2024

AstraZeneca expands late-stage rare disease pipeline with Amolyt Pharma acquisition

AstraZeneca plc (LON:AZN) has entered an agreement to acquire Amolyt Pharma, focusing on treatments for rare endocrine diseases, including hypoparathyroidism...

March 14, 2024

AstraZeneca plc -6.2% potential downside indicated by Deutsche

March 7, 2024

AstraZeneca and Daiichi Sankyo’s Dato-DXd validated by EMA for lung and breast cancer treatment

AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd) receives EMA validation for lung and breast cancer treatments, advancing the potential for improved patient outcomes...

March 4, 2024

AstraZeneca plc -5.4% potential downside indicated by Deutsche

March 1, 2024

AstraZeneca’s Voydeya recommended for PNH treatment in EU

AstraZeneca's Voydeya for PNH patients is recommended for EU approval. Learn about this promising treatment and its potential benefits for patients...